Table 1

Mortality HRs with 750 metabolic equivalent of task (MET) min/week as reference and estimated absolute rate differences per 10 000 person years

MET min/week		0	500	1000	2000	3000	4000	5000	6000
Running (5 mph)^*		0 hour/week	1 hour/week	2 hours/week	4 hours/week	6 hours/week	8 hours/week	10 hours/week	12 hours/week
All cause mortality	Studies	30	35	33	34	17	5	2	3
	Participants^†	812 489	984 339	358 878	465 615	225 616	78 220	4436	97 856
	PY^†	10 324 343	9 532 179	4 007 856	5 235 839	1 910 230	689 649	65 073	48,6671
	Total cases^†	47 141	104 927	36 201	43 861	12 342	3684	246	2962
	HR (95% CI)	1.26 (1.22 to 1.29)	1.06 (1.05 to 1.06)	0.92 (0.91 to 0.93)	0.82 (0.81 to 0.84)	0.83 (0.80 to 0.85)	0.84 (0.79 to 0.90)	0.86 (0.78 to 0.94)	0.88 (0.78 to 0.99)
	ARD (95% CI)^‡	23 (19 to 25)	5 (4 to 5)	−7 (−8 to −6)	−16 (−17 to −14)	−15 (−18 to −13)	−14 (−18 to −8)	−12 (−19 to −5)	−11 (−19 to −1)
CVD mortality	Studies	15	18	18	17	8	2	2	NA
	Participants^†	579 901	986 340	279 319	286 717	111 007	19 489	5488	NA
	PY^†	7 721 115	9 761 494	3 860 943	3 796 251	1 165 769	274 344	65 089	NA
	Total cases^†	12 318	30 196	8618	8661	3258	486	87	NA
	HR (95% CI)	1.34 (1.26 to 1.42)	1.08 (1.07 to 1.10)	0.93 (0.91 to 0.94)	0.81 (0.77 to 0.85)	0.78 (0.69 to 0.87)	0.75 (0.63 to 0.91)	0.73 (0.56 to 0.95)	NA
	ARD (95% CI)‡	8 (6 to 10)	2 (2 to 2)	−2 (−2 to −1)	−5 (−6 to −4)	−5 (−8 to −3)	−6 (−9 to −2)	−7 (−11 to −1)	NA
Cancer mortality	Studies	8	11	10	12	7	6	2	NA
	Participants^†	646 366	994 734	242 136	306 338	124 046	18 831	5488	NA
	PY^†	8 891 975	10 012 834	3 379 697	4 223 768	1 418 477	267 400	65 089	NA
	Total cases^†	11 011	35 570	9034	10 483	4138	557	93	NA
	HR (95% CI)	1.14 (1.11 to 1.17)	1.03 (1.03 to 1.04)	0.95 (0.95 to 0.96)	0.89 (0.86 to 0.92)	0.90 (0.84 to 0.96)	0.91 (0.81 to 1.02)	0.93 (0.79 to 1.09)	NA
	ARD (95% CI)^‡	4 (3 to 5)	1 (1 to 1)	−1 (−1 to −1)	−3 (−4 to −2)	−3 (−4 to −1)	−2 (−5 to 1)	−2 (−6 to 2)	NA
CHD mortality	Studies	6	9	7	7	5	2	1	NA
	Participants^†	281 171	221 650	52 082	25 874	42 668	1092	1411	NA
	PY^†	2 570 415	2 098 520	481 524	331 458	375 410	15 282	7196	NA
	Total cases^†	4430	2020	1094	1010	451	64	8	NA
	HR (95% CI)	1.34 (1.18 to 1.52)	1.09 (1.05 to 1.13)	0.93 (0.91 to 0.95)	0.79 (0.74 to 0.85)	0.74 (0.62 to 0.86)	0.69 (0.52 to 0.91)	0.65 (0.44 to 0.95)	NA
	ARD (95% CI)^‡	6 (3 to 9)	1 (1 to 2)	−1 (−1 to −1)	−3 (−4 to −2)	−4 (−6 to −2)	−5 (−8 to −1)	−6 (−9 to −1)	NA

Dose–response relation between MET min (with 750 MET min as the reference) and mortality HRs estimated with restricted cubic spline regression and generalised least square trend estimation for summarised dose–response data.
*MET min converted into running by dividing by 8.3.9
†Participants, study PY and cases are summed from the following intervals: 0–224=0, 225–749=500, 750–1549=1000, 1550–2549=2000, 2550–3449=3000, 3450–4549=4000, 4550–5549 (5670 for CVD, CHD and cancer)=5000, >5549=6000.
‡Calculated from the HRs and an estimated reference mortality rate (negative values=rate reduction, positive values=rate increase).
ARD, absolute rate difference; CHD, coronary heart disease; CVD, cardiovascular disease; NA, not applicable due to insufficient data; PY, person years.